Research Grants & Contracts was Altimmune’s largest product and service line in fiscal 2018, bringing in $10.31M of $10.33M (100%).
| Product and Service | FY 2017 | FY 2018 |
|---|---|---|
| Research Grants & Contracts | — | $10.31M |
| License Revenue | $41.50K | $19.78K |
| Total | $41.50K | $10.33M |
Altimmune brought in $10.33M from its two product and service lines in fiscal 2018, the year ended December 31, 2018. Altimmune regrouped these lines after fiscal 2017, so the total does not compare directly with that year's $41.50K. Research Grants & Contracts was the largest at $10.31M (99.8%), ahead of License Revenue at $19.78K (0.2%).
Altimmune began breaking out Research Grants & Contracts in fiscal 2018, when it brought in $10.31M.
Altimmune (ALT) reports its revenue by product and service. In fiscal 2018, Research Grants & Contracts was its largest product and service line, bringing in $10.31M (99.8% of the total), followed by License Revenue at $19.78K (0.2%).
Research Grants & Contracts was Altimmune's largest product and service line in fiscal 2018, bringing in $10.31M, or 99.8% of the $10.33M total across its two product and service lines.
Every figure comes from Altimmune's annual financial filings, as reported. Each line keeps the name Altimmune gives it, and years follow its fiscal calendar.
Altimmune's revenue by product and service goes back to fiscal 2017, with figures through fiscal 2018. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.